Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Blepharitis - Overview
Blepharitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Blepharitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Blepharitis - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals Inc
Aperta Biosciences LLC
AxeroVision Inc
Azura Ophthalmics Ltd
Formosa Pharmaceuticals Inc
Hovione FarmaCiencia SA
Merck & Co Inc
NicOx SA
Novaliq GmbH
NTC srl
Premark Pharma GmbH
Quorum Innovations LLC
Sol-Gel Technologies Ltd
Tarsus Pharmaceuticals Inc
Blepharitis - Drug Profiles
APP-13002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AXR-270 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZRBL-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZRBL-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propiote - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lotilaner - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTC-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMP-2207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Qi-402 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Dry Eye and Meibomian Blepharitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tapirof - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Blepharitis - Dormant Projects
Blepharitis - Product Development Milestones
Featured News & Press Releases
Jul 02, 2021: Nicox announces last patient completed NCX 4251 Mississippi phase 2b blepharitis trial
Jun 21, 2021: Tarsus Pharmaceuticals announces positive results of Saturn-1 pivotal trial evaluating TP-03 for the treatment of demodex blepharitis
Jun 18, 2021: Tarsus Pharmaceuticals schedules conference call and webcast to announce saturn-1 phase 2b/3 pivotal trial results for TP-03 for the treatment of Demodex Blepharitis
Jun 01, 2021: Nicox’s completes pre-defined enrollment of NCX 4251 Mississippi phase 2b Blepharitis trial
May 06, 2021: Tarsus Pharmaceuticals initiates Saturn-2, second pivotal phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis
May 03, 2021: Tarsus Pharmaceuticals presents results of pioneering Atlas study at ARVO 2021 annual meeting demonstrating the functiol and psychosocial impact of demodex blepharitis
Apr 23, 2021: Nicox’s NCX 4251 Mississippi Phase 2b blepharitis trial reaches 50% enrollment
Mar 17, 2021: Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Mar 02, 2021: Nicox provides video update on NCX 4251
Jan 19, 2021: Bausch + Lomb completes enrollment of first Phase 3 study for NOV03 (perfluorohexyloctane)
Dec 23, 2020: Tarsus Pharmaceuticals announces Type C meeting with FDA regarding NDA submission requirements for lead candidate TP-03
Dec 15, 2020: Nicox initiates phase 2b trial of NCX 4251, a potential first-in-class treatment for blepharitis
Nov 25, 2020: Bausch Health begins second trial of NOV03 to treat dry eye disease
Oct 13, 2020: Nicox announces plans for NCX 4251 phase 2 trial in blepharitis
Oct 06, 2020: Tarsus releases data from Io and Europa trials for TP-03 to treat demodex blepharitis and begins enrollment and treatment in Phase 2b/3 Saturn-1 trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Blepharitis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Blepharitis, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Blepharitis - Pipeline by Aerie Pharmaceuticals Inc, 2021
Blepharitis - Pipeline by Aperta Biosciences LLC, 2021
Blepharitis - Pipeline by AxeroVision Inc, 2021
Blepharitis - Pipeline by Azura Ophthalmics Ltd, 2021
Blepharitis - Pipeline by Formosa Pharmaceuticals Inc, 2021
Blepharitis - Pipeline by Hovione FarmaCiencia SA, 2021
Blepharitis - Pipeline by Merck & Co Inc, 2021
Blepharitis - Pipeline by NicOx SA, 2021
Blepharitis - Pipeline by Novaliq GmbH, 2021
Blepharitis - Pipeline by NTC srl, 2021
Blepharitis - Pipeline by Premark Pharma GmbH, 2021
Blepharitis - Pipeline by Quorum Innovations LLC, 2021
Blepharitis - Pipeline by Sol-Gel Technologies Ltd, 2021
Blepharitis - Pipeline by Tarsus Pharmaceuticals Inc, 2021
Blepharitis - Dormant Projects, 2021